



55099-A-PCT-US/JPW/AJM/AJD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ilya Trakht

Serial No.: 09/664,485

Examiner: Shanon Foley

Filed: September 18, 2000

Art Unit: 1648

For: DEVELOPMENT OF HUMAN MONOCLONAL ANTIBODIES AND USES
THEREOF

1185 Avenue of the Americas
New York, New York 10036
December 9, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. §1.97(c)(2) to supplement the Information Disclosure Statements filed August 23, 2001 and August 30, 2004 in connection with the above-identified application.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit A**), and attached hereto as **Exhibits 1-8**, respectively:

1. U.S. Patent No. 4,714,681 A, issued December 22, 1987 to Reading et al. (**Exhibit 1**);
2. U.S. Patent No. 5,652,114 A, issued July 29, 1997 to Chu et al. (**Exhibit 2**);
3. European Patent Application No. 0 137 234 A2, published April 17, 1985 (**Exhibit 3**);
4. European Patent Application No. 0 695 760 A1, published February 7, 1996 (**Exhibit 4**);
5. European Patent Application No. 0 799 836 A1, published

Applicant: Ilya Trakht
Serial No.: 09/664,485
Filed: September 18, 2000
Page 2

October 8, 1997 (**Exhibit 5**);

6. PCT International Publication No. WO 94/27638 A, published December 8, 1994 (**Exhibit 6**);
7. Carroll, W.L., Thielemans, K., Dilley, J. and Levy, R. (1986) Mouse x human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 89: 61-72 (**Exhibit 7**); and
8. Kearney, J.F., Radbruch, A., Liesegang, B. and Rajewsky K. (1979) new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123: 1548-1550 (**Exhibit 8**).

The Examiner is respectfully requested to make these references of record in the present application by initialing and returning a copy of the enclosed Form PTO-1449.

Applicant notes that the above-listed references were previously cited in a Supplementary European Search Report issued November 23, 2004 in connection with European Patent Application No. 99913925.6, a foreign counterpart of the subject application. References 7 and 8 listed above were also cited in a Supplementary Partial European Search Report issued September 8, 2004 in connection with the same European application. A copy of the November 23, 2004 Supplementary European Search Report is attached hereto as **Exhibit B**, and a copy of the September 8, 2004 Supplementary Partial European Search Report is attached hereto as **Exhibit C**.

Applicant notes also that the Kozbor et al. (1884) and Östberg et al. (1983) references cited in each of the above-identified European Search Reports (**Exhibits B and C**) are not listed in the present Supplemental Information Disclosure Statement because

Applicant: Ilya Trakht
Serial No.: 09/664,485
Filed: September 18, 2000
Page 3

these references were previously made of record in the subject application, having been cited to the Examiner as references 34 and 37, respectively, in the Information Disclosure Statement filed August 23, 2001. Similarly, U.S. Patent Nos. 4,689,299 and 5,215,913 cited in the November 23, 2004 Supplementary European Search Report (**Exhibit B**) are not listed herein because they were previously disclosed as references 7 and 22, respectively, in the August 23, 2001 Information Disclosure Statement.

If a telephone conference would be of assistance in advancing the prosecution of the subject application, applicant's undersigned attorneys invite the Examiner to telephone them at the number provided below.

Pursuant to 37 C.F.R. §1.97(c)(2) and 1.17(p), a fee of one hundred and eighty dollars (\$180.00) is required for filing this Supplemental Information Disclosure Statement. Accordingly, a check in the amount of ONE HUNDRED EIGHTY DOLLARS (\$180.00) is enclosed. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Mail Stop Amendment, Commissioner for
Patents, P.O. Box 1450 Alexandria, VA
22313-1450

12/5/04
Alan J. Morrison
Reg. No. 37,399

Date

<p>Form PTO-144 U.S. Department of Commerce Patent and Trademark Office</p> <p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>										Atty. Docket No. 55099-A-PCT-US /JPW/AJM/AJD	Serial No. 09/664,485				
										Applicant(s) Ilya Trakht					
										Filing Date September 18, 2000	Group Art Unit 1648				
U.S. PATENT DOCUMENTS															
Examiner Initials	Exh. No.	Document Number								Date	Name	Class	Subclass	Filing Date If Appropriate	
	1	4	7	1	4	6	7	8	12/22/87	Reading et al.					
	2	5	6	5	2	1	1	4	07/29/97	Chu et al.					
FOREIGN PATENT DOCUMENTS															
		Document Number								Date	Country	Class	Subclass	Translation	
		3	0	1	3	7	2	3	4	04/17/85	EPO			Yes	No
		4	0	6	9	5	7	6	0	02/07/96	EPO				
		5	0	7	9	9	8	3	6	10/08/97	EPO				
		6	9	4	2	7	6	3	8	12/08/94	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
	7	Carroll, W.L., Thielemans, K., Dilley, J. and Levy, R. (1986) Mouse x human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 89: 61-72; and													
	8	Kearney, J.F., Radbruch, A., Liesegang, B. and Rajewsky K. (1979) A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123: 1548-1550.													
EXAMINER								DATE CONSIDERED							
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>															